INCY News and Press, Incyte Corporation From 12/06/20

Source: Press release"We are pleased both with the response rates and consistency of the results we are seeing in MANIFEST,"says Constellation Pharmaceuticals (CNST) CEO Jigar Raythatha. "In addition, we are excited by results from our translational studies that suggest that CPI-0610 may...

- Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 - Findings from the study are being presented at ASH 2020, and complement previously-reported positive results for Jakafi in steroid-refractor...

IMV (IMV) announces updated data from a Phase 2 clinical trial, DeCidE1, evaluating DPX-Survivac, combined with intermittent low-dose cyclophosphamide (chemo agent), in patients with recurrent advanced platinum-sensitive and platinum-resistant ovarian cancer.78.9% (n=15/19) of evaluable patie...

Back on Dec. 29, 2019, I published an article here on Seeking Alpha, "Incyte Corporation: Wait And Watch." Those who waited and watched would have been well rewarded, with significantly lower share prices through all of January, February and March. Again on July 31, 2020, I publis...

Kinnate Biopharma (KNTE) has raised the proposed deal size for its upcoming IPO.The company now plans to raise $213M by offering 11.5M shares at a price range of $18 to $19 vs. original offering of 10M shares at a range of $16 to $18.Kinnate is focused on the discovery and development of...

Triple-negative Breast Cancer (TNBC) is a highly aggressive subtype that accounts for 15-20% of breast cancer cases and 25% of all breast cancer deaths . Unlike other breast cancers, treatments for TNBC involving hormone therapy and drugs that target HER2 protein are not helpful . W...

Kinnate Biopharma aims to raise $170 million in an IPO. The firm is developing kinase inhibitor-based treatment candidates for various cancers. KNTE has produced promising results in preclinical studies, but is still extremely high risk; the IPO may be more suited to long-term hol...

MacroGenics (MGNX) has received $25M in milestone payment from Incyte (INCY), related to retifanlimab, an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA0012). The payment was triggered by recent initiation of POD1UM-303, ...

Eli Lilly (LLY) and Incyte (INCY) say the U.S. Food and Drug Administration issued an emergency use authorization for their baricitinib arthritis drug in combination with Gilead Sciences' (GILD) remdesivir to treat hospitalized patients with COVID-19."This is an important milestone for hospit...

Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19 - ACTT-2 data serve as basis for EUA, the second COVID-19 authorization for a Lilly treatment - Authorization enables use of baricitinib in combination with...